论文部分内容阅读
目的探讨胎盘多肽注射液在高龄食管癌临床治疗中的应用价值。方法将四川省人民医院2011年1月—2013年1月期间收治的78例行手术治疗的高龄食管癌患者随机分为2组,即观察组39例,对照组39例。对照组39例患者行单纯化疗治疗,观察组39例患者在上述化疗治疗的基础上行胎盘多肽注射液治疗。分别对2组患者的临床治疗效果进行评价;检测2组患者治疗前后的免疫功能指标CD3+、CD4+及NK细胞活性,评价患者的免疫功能;同时观察并统计2组患者的无进展生存时间(progression-free survival,PFS)和总生存期(overall survival,OS)。结果观察组39例患者临床治疗的总有效率为64.10%,对照组为61.54%,2组比较,差异具有统计学意义(P<0.01)。治疗后,观察组患者的平均免疫功能指标CD3+、CD4+及NK细胞活性水平依次为(48.35±6.21)%、(34.67±4.18)%、(29.45±4.33)%,对照组依次为(27.32±4.36)%、(20.44±5.34)%、(18.32±4.36)%。2组比较,差异具有统计学意义(P<0.01)。观察组患者的平均PFS和OS依次为(8.4±1.3)个月、(12.4±2.2)个月;对照组依次为(5.2±1.2)个月、(9.3±2.4)个月。2组比较,差异具有统计学意义(P<0.01)。结论高龄食管癌患者行化疗治疗的同时辅助胎盘多肽注射液治疗不仅不对临床治疗效果造成影响,且能有效提高患者的机体免疫功能,并延长患者的PFS和OS,值得临床推广应用。
Objective To investigate the value of placental peptide injection in the clinical treatment of advanced esophageal cancer. Methods Seventy-eight patients with esophageal cancer who underwent surgery in Sichuan Provincial People’s Hospital from January 2011 to January 2013 were randomly divided into two groups, 39 in the observation group and 39 in the control group. 39 patients in the control group were treated with chemotherapy alone, 39 patients in the observation group were treated with placental peptide injection on the basis of the above chemotherapy. The clinical effects of two groups of patients were evaluated respectively. The immune function indexes CD3 +, CD4 +, and NK cell activity were measured before and after treatment to evaluate the immune function of the two groups. At the same time, the progression-free survival time -free survival, PFS) and overall survival (OS). Results The total effective rate of clinical observation was 64.10% in 39 cases of observation group and 61.54% in control group. There was significant difference between the two groups (P <0.01). After treatment, the average level of CD3 +, CD4 + and NK cell activity in the observation group were (48.35 ± 6.21)%, (34.67 ± 4.18)% and (29.45 ± 4.33)%, respectively, and in the control group were (27.32 ± 4.36 )%, (20.44 ± 5.34)%, (18.32 ± 4.36)%. The difference between the two groups was statistically significant (P <0.01). The mean PFS and OS in the observation group were (8.4 ± 1.3) months and (12.4 ± 2.2) months, respectively, while those in the control group were (5.2 ± 1.2) and (9.3 ± 2.4) months, respectively. The difference between the two groups was statistically significant (P <0.01). Conclusions Chemotherapy with adjuvant placental peptide injection in elderly patients with esophageal cancer not only does not affect the clinical treatment effect, but also can effectively improve the immune function and extend the PFS and OS in patients with esophageal cancer, which is worthy of clinical application.